Patents for A61P 35 - Antineoplastic agents (221,099)
03/2011
03/29/2011CA2412750C Substituted metal-phthalocyanines, their preparation and the use thereof
03/29/2011CA2397016C Use of lipid conjugates in the treatment of disease
03/29/2011CA2390652C Human circulating virus-inhibiting peptide (virip) and its use
03/29/2011CA2390164C Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
03/29/2011CA2387611C Manufacture of polyglutamate-therapeutic agent conjugates
03/29/2011CA2345276C Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
03/29/2011CA2323058C Methods for the diagnosis and treatment of lung cancer by detection of proto-oncogene overexpression
03/29/2011CA2263798C G-coupled receptor showing selective affinity for atp
03/29/2011CA2239151C Integrin-linked kinase, its inhibitors and methods of medical treatment using these inhibitors, gene therapy and pseudo-substrate inhibitors
03/29/2011CA2207815C Modulators of the function of fas/apo1 receptors
03/29/2011CA2165573C Anti-.alpha.v-integrin monoclonal antibody
03/24/2011WO2011035143A2 Methods and compositions for inhibiting rho-mediated diseases and conditions
03/24/2011WO2011034934A1 Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
03/24/2011WO2011034919A2 Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer
03/24/2011WO2011034887A2 A method for treating neuropathic pain
03/24/2011WO2011034834A2 Pharmaceutical compositions which inhibit fkbp52-mediated regulation of androgen receptor function and methods of using same
03/24/2011WO2011034775A2 Methods for treating brain tumors
03/24/2011WO2011034583A2 Inhibition of endosomal toll-like receptor activation
03/24/2011WO2011034504A1 Solid forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and methods of making the same
03/24/2011WO2011034465A1 A pharmaceutical composition for peroral administration of diindolylmethane
03/24/2011WO2011034394A2 Oxaliplatin nanoparticles and method for preparing same
03/24/2011WO2011034215A1 COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY
03/24/2011WO2011034210A1 Pharmaceutical combination for treating tumor
03/24/2011WO2011033265A1 Pharmaceutical compounds
03/24/2011WO2011033229A1 Acetylene derivatives of 5-phenyl-pyrazolopyridine, preparation thereof, and therapeutic use thereof
03/24/2011WO2011033225A2 Substituted 3-amino-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof
03/24/2011WO2011033105A1 Dosage regimen for administering an epcamxcd3 bispecific antibody
03/24/2011WO2011033053A1 Macrocyclic inhibitors of jak
03/24/2011WO2011032563A1 Medical use of spla2 hydrolysable liposomes
03/24/2011WO2011032491A1 Selfheal extraction containing rosmarinic acid, its preparation method and its use for preparation of medicine for precaution or treatment of cancer metastasis after surgery
03/24/2011WO2011032489A1 Method of using poxvirus vector hiv vaccine combined with adenoviral vector hiv vaccine and the uses thereof
03/24/2011WO2011032296A1 Methods and compositions for the diagnosis and treatment of thyroid cancer
03/24/2011WO2011012885A9 Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer
03/24/2011WO2011009095A8 Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
03/24/2011WO2010148007A9 Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
03/24/2011WO2010136000A3 Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them
03/24/2011WO2010132684A3 Inhibitors of inv(16) leukemia
03/24/2011WO2010129053A3 Egfr inhibitors and methods of treating disorders
03/24/2011WO2010129048A3 Therapeutic compounds
03/24/2011WO2010123591A3 Small molecule inhibitors of nads, namnat, and nmnat
03/24/2011WO2010123583A3 1-aryl or 1-heteroaryl-pyrido[b]indoles and uses thereof
03/24/2011WO2010120872A3 Method of decreasing pro-adam10 secretase and/or beta secretase levels
03/24/2011WO2010118200A3 Liposomal formulations of tocopheryl amides
03/24/2011WO2010111653A3 Modulating ires-mediated translation
03/24/2011WO2010108125A3 Psma-targeting compounds and uses thereof
03/24/2011WO2010091384A3 Cadherin-11 inhibitors and methods of use thereof
03/24/2011WO2010022358A8 6-substituted 2-(benzimidazolyl)purine and purinone derivatives and 6-substituted 2-(imidazolo[4,5- c]pyridinyl)purine and purinone derivatives for immunosuppression
03/24/2011US20110071612 Anti-angiogenic compositions and methods of use
03/24/2011US20110071216 Reconstitutable reverse thermal gelling polymers
03/24/2011US20110071215 Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
03/24/2011US20110071214 Methods and compositions for the treatment of cancer
03/24/2011US20110071212 P185neu-encoding dna and therapeutical uses thereof
03/24/2011US20110071211 MicroRNA (miRNA) And Downstream Targets For Diagnostic And Therapeutic Purposes
03/24/2011US20110071210 Methods and compositions for the treatment of cancer or other diseases
03/24/2011US20110071208 Lipid encapsulated dicer-substrate interfering rna
03/24/2011US20110071196 Compounds Which Selectively Modulate The CB2 Receptor
03/24/2011US20110071195 Novel alkene oxindole derivatives
03/24/2011US20110071182 Inhibitors of AKT Activity
03/24/2011US20110071179 Macrocyclic inhibitors of jak
03/24/2011US20110071178 Methods and Compounds for Modulating Cannabinoid Activity
03/24/2011US20110071174 Substituted quinazolines
03/24/2011US20110071172 Substituted quinazolines as blood platelet lowering agents
03/24/2011US20110071171 2h- pyrimido [2, 1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents
03/24/2011US20110071170 Tricyclic pyrazolopyrimidine derivatives
03/24/2011US20110071169 Preparation of polymorphic form of lapatinib ditosylate
03/24/2011US20110071165 Aza- and polyazanthranyl amides and their use as medicaments
03/24/2011US20110071158 New compounds
03/24/2011US20110071157 Role of N-2-Hydroxy-Ethyl-Piperazine-N'-2-Ethane Sulfonic Acid (HEPES) in Pain Control and Reversal of Demyelinization Injury
03/24/2011US20110071153 Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors
03/24/2011US20110071151 Abt-263 crystalline forms
03/24/2011US20110071149 Selective kinase inhibitors
03/24/2011US20110071147 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
03/24/2011US20110071145 Raf Modulators And Methods Of Use
03/24/2011US20110071144 Quinazoline derivatives and pharmaceutical compositions containing them
03/24/2011US20110071142 Identification and use of small molecules to modulate transcription factor function and to treat transcription factor associated diseases
03/24/2011US20110071136 Novel tricyclic protein kinase modulators
03/24/2011US20110071134 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
03/24/2011US20110071133 Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
03/24/2011US20110071127 Compounds Which Modulate the CB2 Receptor
03/24/2011US20110071125 Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity
03/24/2011US20110071115 Pharmaceutically useful heterocycle-substituted lactams
03/24/2011US20110071113 Thiazole Derivatives and Use Thereof
03/24/2011US20110071100 Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases
03/24/2011US20110071099 Cationic Ceramides, And Analogs Thereof, And Their Use For Preventing Or Treating Cancer
03/24/2011US20110071097 Cephalotaxus esters, methods of synthesis, and uses thereof
03/24/2011US20110071094 (d)-allose inducing programmed cell death in hormone refractory prostate cancer lines
03/24/2011US20110071090 Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
03/24/2011US20110071089 Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity
03/24/2011US20110071087 Polypeptides having modulatory effects on cells
03/24/2011US20110071083 Modification of the properties of a fibrin matrix with respect to growth and ingrowth of cells
03/24/2011US20110071082 Long lasting anti-angiogenic peptides
03/24/2011US20110070317 Pyrrolopyridines as kinase inhibitors
03/24/2011US20110070314 Methods for treating brain tumors
03/24/2011US20110070313 Methods of inducing cell differentiation with placental extracts
03/24/2011US20110070311 Producing a sustained-release preparation
03/24/2011US20110070298 Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
03/24/2011US20110070295 Methods for the preparation of liposomes comprising docetaxel
03/24/2011US20110070294 Methods for the Administration of Drugs Using Liposomes
03/24/2011US20110070293 Methods for the Preparation of Liposomes Comprising Docetaxel
03/24/2011US20110070292 Methods For The Preparation Of Liposomes